EP1027073A2 - Effets renforces pour therapeutique associee a l'haptene - Google Patents

Effets renforces pour therapeutique associee a l'haptene

Info

Publication number
EP1027073A2
EP1027073A2 EP97949336A EP97949336A EP1027073A2 EP 1027073 A2 EP1027073 A2 EP 1027073A2 EP 97949336 A EP97949336 A EP 97949336A EP 97949336 A EP97949336 A EP 97949336A EP 1027073 A2 EP1027073 A2 EP 1027073A2
Authority
EP
European Patent Office
Prior art keywords
therapeutic compound
peptide
therapeutic
moiety
haptenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97949336A
Other languages
German (de)
English (en)
Inventor
Roland Buelow
Alexander R. Lussow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangstat Medical Corp
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of EP1027073A2 publication Critical patent/EP1027073A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Definitions

  • the field of this invention is modification of the pharmacokinetics and pharmacodynamics of drugs or biologicals in vivo, specifically, for enhancing the effective in vitro half-life of therapeutic compounds in mammals .
  • a "Xenoject” compound is a conjugate of a therapeutic compound and a haptenic moiety which, when administered to a mammalian host, is recognized and bound by circulating antibodies directed against the haptenic moiety, thereby effectively increasing the in vivo half-life of the therapeutic compound in the vascular system.
  • Therapeutic compounds are conjugated to haptenic moieties that are recognized and bound by circulating antibodies in vivo.
  • the therapeutic compound/hapten conjugates referred to herein as "Xenoject compounds”
  • Xenoject compounds have an increased effective in vivo half-life as compared to that of the unconjugated therapeutic compound.
  • the increase in in vivo duration is due, at least in part, to binding of the haptenic moiety of the Xenoject compound to the antigen binding site of a circulating antibody, thereby resulting in a stabilization of the drug in the serum.
  • the drug then remains in the circulation with a half-life more closely resembling that of an immunoglobulin molecule rather than of a free small molecule. This allows lower doses of the therapeutic to be used which is of particular benefit when the compound is inherently toxic.
  • Figure 1 illustrates the enhanced effects of binding a therapeutic compound to circulating antibodies via a haptenic moiety.
  • Transplanted ⁇ -galactosyltransferase knock-out mice each of which had high-titers of circulating anti- ⁇ -Gal antibodies, were treated for 10 days with 1 mg/Kg of D-Allotrap/ ⁇ -Gal conjugate (•) , unconjugated D-Allotrap (O) , or no peptide (D) .
  • Cardiac graft survival was measured by direct palpation of the hearts through the peritoneum. Results were plotted as the percent graft survival over time after transplantation.
  • methods for prolonging the effective in vivo half-life of a therapeutic compound in a mammal comprise conjugating the therapeutic compound to a haptenic moiety to provide a therapeutic compound-hapten conjugate (herein also referred to as a "Xenoject compound") .
  • a therapeutic compound-hapten conjugate herein also referred to as a "Xenoject compound”
  • the haptenic moiety of the conjugate is recognized and bound by a circulating antibody present in the mammal which is directed against that hapten, thereby serving to stabilize the conjugate in the mammalian vascular system.
  • the therapeutic compound thereby exhibits an effective half-life that more closely resembles that of an immunoglobulin molecule rather than that of a free small molecule in the vascular system.
  • therapeutic compound refers to any compound that, when administered to a mammalian subject, gives rise to a desired therapeutic effect.
  • Therapeutic compounds that find use in the presently described methods include, for example, peptides, including for example, Allotrap peptides and cyclosporines, peptidomimetics, proteins, including for example, immunoglobulins or therapeutically effective fragments thereof, hormones, including for example estrogens, progesterones, growth hormone, and the like, enzymes, enzyme inhibitors, interleukins, including interleukin-2 , cytokines, growth factors, nucleic acids, chemical compounds, including organic compounds, metallic compounds, chemotherapeutic compounds, and the like, and radioactively labeled compounds.
  • the therapeutic compound is not critical to the invention in that virtually any therapeutic compound can be successfully conjugated to a hapten provided that the compound possesses a site at which the hapten can be conjugated without substantially affecting the therapeutic activity of the compound.
  • Therapeutic compounds which find use in the methods of the present invention may be naturally occurring or synthetic. Such compounds may also be "biologically active" in their native state, meaning that the compound itself possesses the ability to provide a desired therapeutic effect without any modification of that compound. On the other hand, therapeutic compounds that find use may also be biologically inactive or in a latent precursor state when administered as part of a therapeutic compound/hapten conjugate, but may acquire biological or therapeutic activity when a portion of the therapeutic compound is hydrolyzed, enzy ⁇ natically cleaved or is otherwise modified in the mammalian vascular system or at the specific target site.
  • the therapeutic compound may be a "pro-drug" , meaning that the compound is essentially therapeutically inactive when administered but becomes active upon modification in the vascular system.
  • specific hydrolyzable groups may be attached to therapeutic compounds by methods known in the art, said hydrolyzable groups being hydrolyzed after administration of the conjugate to the mammal, thereby resulting in activation of the therapeutic compound.
  • the essentially inactive therapeutic compound may be enzymatically cleaved or otherwise modified in the vascular system to provide for the biologically active compound.
  • An example of such a precursor therapeutic compound is, for example, pro-insulin.
  • the pro-drug may be modified in the vascular system over time to provide a large depot of active drug or may remain inactive until it reaches a specific target site.
  • the therapeutic compound Once activated by hydrolysis, enzymatic cleavage or by other modification, the therapeutic compound may act at the surface of a target cell or may be transported into the target cell to act intracellularly.
  • prolonging the in vivo half life of a therapeutic compound By “prolonging the in vivo half life of a therapeutic compound” , “stabilizing" a therapeutic compound or grammatical equivalents thereof is meant that the in vivo half -life of a therapeutic compound when conjugated to a haptenic moiety is increased relative to the in vivo half- life of the same therapeutic compound that is not conjugated to a haptenic moiety.
  • Techniques for determining the in vivo half life of therapeutic compounds are well known and conventionally used in the art and include, for example, determining the presence and/or activity of the therapeutic compound in the vascular system over time.
  • Haptenic moieties that find use for conjugation to a therapeutic compound of interest are specifically recognized and bound by circulating antibodies present in the mammalian vascular system and include, for example, xenoantigens, including, for example, sugar moieties typically found on glycoproteins such as Gal ⁇ l-3 Gal and mimetics of those sugar moieties (e.g., see Vauehan et al . , Xeno transplantation 3:18-23 (1996)), blood group antigens, and the like.
  • Haptenic moieties may also comprise immunodominant epitopes of vaccines including, for example, epitopes derived from diphtheria or tetanus toxin, influenza virus hemagglutinin, HBs antigen, hepatitis A or B virus, polio virus, rubella virus, measles virus, tuberculosis virus, and the like.
  • the haptenic moiety may comprise an alloantigen such as, for example, a fragment of a major histocompatibility antigen to which the host has been previously sensitized.
  • Conjugation of the therapeutic compound to the haptenic moiety results in the production of a "therapeutic compound- hapten conjugate".
  • the therapeutic compound and the haptenic moiety may be covalently or non-covalently attached and may be joined directly through a chemical bond or through a bridge of not more than about 50 members in the chain, usually not more than about 20 members in the chain, where the members of the chain may be carbon, nitrogen, oxygen, sulfur, phosphorus, and the like.
  • various techniques may be used to join the two members of the therapeutic compound-hapten conjugate, depending upon the nature of the members of the conjugate, the binding sites of the members of the conjugate, convenience, and the like.
  • Functional groups that may be involved in the covalent conjugation of the members include esters, amides, ethers, phosphates, amino, hydroxy, thio, aldehyde, keto, and the like.
  • the bridge may involve aliphatic, alicyclic, aromatic, or heterocyclic groups.
  • the haptenic moiety may be "built into” the therapeutic compound during synthesis of that compound or may be conjugated to the therapeutic compound after that compound has been fully synthesized or otherwise obtained.
  • the haptenic moiety may be conjugated to a reactive site on one or more of the amino acids which are present in the compound, either on a reactive side chain of an amino acid or at the C- or N-terminus of the peptide or protein.
  • amino acids such as lysine, arginine, glutamic acid, aspartic acid and others possess chemically reactive sites available for covalent conjugation to the haptenic moiety.
  • Non-covalently linked conjugates may be prepared, for example, through biotin-avidin interactions, and the like.
  • Conjugates involving only proteins or glycoproteins can be chimeric or fusion recombinant molecules resulting from expression of ligated open reading frames of natural sequences, synthetic sequences, or combinations thereof.
  • the particular manner in which the haptenic moiety is joined to the therapeutic compound will not be critical to the invention so long as the haptenic moiety is available for binding to circulating antibodies in the vascular system.
  • the ⁇ -galactosyl group may be conjugated to the therapeutic compound in a variety of ways.
  • the number of therapeutic compounds conjugated to each haptenic moiety may vary. In some situations, it may be desirable to have more than one therapeutic compound joined .to each haptenic moiety to provide, for example, for a higher avidity between the conjugate and the target of interest. Generally, the number of therapeutic compounds conjugated to a haptenic moiety will be a function of the size and structure of the therapeutic compound and will usually be less than about 5, more usually less than about 3, frequently less than about 2 and most frequently 1. Moreover, in some instances, a higher ratio of haptenic moieties to therapeutic compounds may also be employed.
  • the subject Xenoject compounds can be used for the treatment of a wide variety of pathologies simply by varying the therapeutic compound employed.
  • treatments may include such things as immunosuppression for organ transplantation, treatment of neoplasias such as carcinomas, leukemias, lymphomas, sarcomas, melanomas, and the like, hormonal therapy, treatment of bacterial or viral infection, etc .
  • the Xenoject compounds of the present invention will usually be administered to a mammalian subject as a bolus, but may be introduced slowly over time by infusion using metered flow, or the like.
  • the Xenoject compounds will usually be administered in a physiologically acceptable medium, e.g. deionized water, phosphate buffered saline, saline, aqueous ethanol or other alcohol, plasma, proteinaceous solutions, mannitol, aqueous glucose, alcohol, vegetable oil, or the like.
  • additives which may also find use include buffers, where the media are generally buffered at a pH in the range of about 5 to 10, where the buffer will generally range in concentration from about 50 to 250 mM salt, where the concentration of salt will generally range from about 5 to 500 mM, physiologically acceptable stabilizers, biocides, and the like, these additives being conventional and used in conventional amounts.
  • the Xenoject compounds described herein will for the most part be administered parenterally, such as intravascularly, intravenously, intraarterially, intramuscularly, subcutaneously, or the like, however, administration may also be orally, nasally, rectally, transdermally or inhalationally via an aerosol.
  • the Xenoject compounds may be administered by any convenient means, including syringe, trocar, catheter, or the like. The particular manner of administration will vary depending upon the amount to be administered, whether a single bolus or continuous administration, or the like. Often the administration will be intravascularly, where the site of introduction is not critical to this invention, preferably at a site where there is rapid blood flow so as to provide for systemic dissolution of the compound, e.g. intravenously, peripheral or central vein. The Xenoject compounds may also be administered locally so as to direct the compounds to a specific site.
  • the haptenic moiety of the therapeutic compound-hapten conjugate will be specifically recognized and bound by a circulating antibody present in the mammalian host.
  • the circulating antibodies which serve to bind to and stabilize the Xenoject compound can be naturally occurring antibodies such as antibodies directed against, for example, blood group antigens, and the like, or anti-xenogenic antibodies.
  • Antibodies that serve to bind to and stabilize the Xenoject compound may also be those induced in response to a prior presensitization of the mammalian host by, for example, a fragment of a major histocompatibility antigen, or in response to a prior vaccination of the mammalian host by, for example, diphtheria or tetanus antitoxin, influenza virus hemagglutinin, HBs antigen, hepatitis A or B virus, polio virus, rubella virus, measles virus, tuberculosis virus, etc.
  • the host can be presensitized to the particular hapten of interest prior to administration of the Xenoject compound.
  • Allotrap efficacy by prolongation of its in vivo half-life Potent immunosuppressive peptides have been identified from the amino acid sequence of the human leukocyte antigen class I molecule. Clayberger and Krensky, supra . These peptides are known as Allotrap peptides and have been demonstrated to have immunosuppressive effects leading to the prolongation of organ allograft survival. Recent reports have demonstrated that there is a significant therapeutic advantage to effectively increasing the in vivo half life of Allotrap peptides by rendering those peptides resistant to hydrolysis by serum proteases. Gao et al . , supra. This was accomplished by synthesizing the D-amino acid isomer of the natural peptide (D-Allotrap peptide) .
  • D-Allotrap peptide sequence was linked to the haptenic moiety Gal ⁇ l-3 Gal-NHS and tested in mice having naturally occurring circulating anti- ⁇ -Gal antibodies.
  • the D-Allotrap/ ⁇ -Gal Xenoject conjugates were demonstrated to bind to the circulating antibodies, survive for a significantly longer period in the circulation than do the unconjugated D- Allotrap peptides and have enhanced immunosuppressive effects as compared to the unconjugated D-Allotrap peptide.
  • Gal antigen, peptides and conjugates The synthesis of the peptide-sugar conjugate first required the generation of an ⁇ -Gal disaccharide with a reactive group on the first carbon of the galactosyl ring. Briefly, this was accomplished by generating two bromine protected ring compounds (2,3,4, 6-tetra-0-benzyl- ⁇ -D-galactopyranosyl bromide and 4,6-0- benzylidene-1, 2-0-isopylidene- ⁇ -D-galactopyranose) .
  • this structure was added to the secondary amine on the epsilon carbon of lysine (termed ⁇ -Gal-s-Lys where Lys is lysine) .
  • the Allotrap D-B2702 amino acid sequence (Arg-Glu-Asn-Leu-Arg-Ile-Ala-Leu-Arg-Tyr) was then constructed with an automated peptide synthesizer (Synpep, Dublin, CA) such that the ⁇ -Gal-s-Lys was incorporated into the final peptide product. This resulted in a conjugate retaining its peptide immunosuppressive function that was capable of binding to anti- ⁇ -Gal antibodies.
  • mice were available that had an inactivated ⁇ -galactosyltransferase gene
  • mice were treated for 10 days (lmg/Kg) with the unconjugated D-Allotrap peptide or with the D-Allotrap/ ⁇ -Gal conjugate, and the survival of the transplanted hearts was compared to those from mice that received no treatment. As shown in Figure 1, the mice treated with unconjugated D-Allotrap peptide maintained their grafts for roughly 5 days longer (rejection on day 15) than did the untreated anneals.
  • mice treated with the D-Allotrap/ ⁇ -Gal conjugate preserved their graft function for 25 days (rejection on day 35) beyond the untreated controls . This indicated that there was a significant advantage to conjugating the therapeutic peptide to a haptenic moiety.
  • the purported target for Allotrap peptide action may be an intracellular molecule (such as hsp 70; see Nossner et al . , supra) , it was unlikely that the enhanced activity of the D-Allotrap/ ⁇ -Gal conjugate was due to redirection of the circulating antibodies to a specific target such that the immunoglobulins would then activate, complement and kill the cell. Instead, it was postulated that the therapeutic peptide was benefiting from a prolonged half -life in the serum when the haptenic moiety of the conjugate was bound to circulating serum immunoglobulins.
  • (+) indicates that the D-Allotrap peptide was recovered from the serum sample, and (-) indicates that it was not.

Abstract

L'invention a trait à de nouvelles méthodes permettant de renforcer la demi-vie efficace in vivo de composés thérapeutiques chez des mammifères. Plus particulièrement, ces composés thérapeutiques sont associés à une fraction haptène. A la suite de l'administration au mammifère, les conjugats - composé thérapeutique/haptène - sont fixés par des anticorps circulant dirigés de manière spécifique contre la fraction haptène du conjugat, ce qui se solde par une stabilisation du conjugat dans le système vasculaire et une augmentation réelle de la demi-vie in vivo du composé thérapeutique.
EP97949336A 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene Withdrawn EP1027073A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75267196A 1996-11-19 1996-11-19
US752671 1996-11-19
PCT/US1997/018475 WO1998022141A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene

Publications (1)

Publication Number Publication Date
EP1027073A2 true EP1027073A2 (fr) 2000-08-16

Family

ID=25027301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97949336A Withdrawn EP1027073A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene

Country Status (3)

Country Link
EP (1) EP1027073A2 (fr)
AU (1) AU7298398A (fr)
WO (1) WO1998022141A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1121425B1 (fr) 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Peptides bioactifs stabilises, procedes d'identification, synthese et utilisation
WO2001032207A1 (fr) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Procede permettant d'appliquer une immunotherapie active/passive
ATE337403T1 (de) * 1999-12-24 2006-09-15 Genentech Inc Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP1757311B1 (fr) * 1999-12-24 2009-02-11 Genentech, Inc. Méthodes et compositions pour la prolongation de la demi-période d'élimination de composés bioactifs
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
WO2008074839A2 (fr) 2006-12-19 2008-06-26 Ablynx N.V. Séquences d'acides aminés dirigées contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles liés au gpcr
EP2514767A1 (fr) 2006-12-19 2012-10-24 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille ADAM et polypeptides les comprenant pour le traitement de maladies et troubles liés à ADAM
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
EP2313436B1 (fr) 2008-07-22 2014-11-26 Ablynx N.V. Séquences d acides aminés dirigées contre des récepteurs de désactiveurs multicibles et polypeptides
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
KR101832040B1 (ko) 2010-11-08 2018-04-04 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
IN2014CN00437A (fr) 2011-06-23 2015-04-03 Ablynx Nv
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (fr) 2012-12-07 2014-06-12 Ablynx N.V. Polypeptides améliorés dirigés contre ige
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
CA3043515A1 (fr) 2016-11-16 2018-05-24 Ablynx Nv Polypeptides de recrutement de lymphocytes t capables de se lier a cd123 et tcr alpha/beta
AR112069A1 (es) 2017-06-02 2019-09-18 Ablynx Nv Inmunoglobulinas que fijan aggrecan
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
EP3774917A4 (fr) 2018-03-30 2022-01-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique contre lag-3 et leurs utilisations
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
AU2705795A (en) * 1994-06-16 1996-01-05 Board Of Trustees Of The Leland Stanford Junior University Immune modulation with class ii alpha-chain fragments
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
AU1823697A (en) * 1996-01-02 1997-07-28 Board Of Trustees Of The Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
JPH10511989A (ja) * 1996-04-10 1998-11-17 サングスタット メディカル コーポレイション 特異的結合ペア構成要素の細胞調節性複合体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9822141A2 *

Also Published As

Publication number Publication date
WO1998022141A2 (fr) 1998-05-28
AU7298398A (en) 1998-06-10
WO1998022141A3 (fr) 1999-01-07

Similar Documents

Publication Publication Date Title
WO1998022141A2 (fr) Effets renforces pour therapeutique associee a l'haptene
AU706723B2 (en) Amplification of the VB-12 uptake system using polymers
KR100290632B1 (ko) 면역성이약한항원공액체와이를포함하는합성펩티드담체와백신
US20070134259A1 (en) Methods and compositions for pharmacologially controlled targeted immunotherapy
EP2245047B1 (fr) Peptides issus de pres modifiés hydrophobes du virus de l'hépatite b (vhb) et leur utilisation en tant que véhicules pour l'administration spécifique de composés au foie
Kowalczyk et al. Peptide lipidation–a synthetic strategy to afford peptide based therapeutics
EP1034795A2 (fr) Conjugués de lipides et de composés biologiquement actif
JPH0674210B2 (ja) 抗原の免疫原性の増強
EP2673004A1 (fr) Peptides modifiés hydrophobes et leur utilisation pour un ciblage hépatique spécifique
ES2210514T3 (es) Conjugados citomoduladores de miembros de pares de union especificos.
US5043158A (en) Immunogenic compositions containing ordered carriers
JP2020037701A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
US9849174B2 (en) Methods and compositions related to immunogenic fibrils
CN104936613B (zh) 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
DE69534382T2 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
JP5802553B2 (ja) ペプチジルジアシルグリセリド
KR20070122563A (ko) 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
US7314956B2 (en) Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
JP2001521733A (ja) ヒト上皮増殖因子とヒトアンギオゲニンの融合タンパク質およびその製造方法
JPH07507541A (ja) 糖尿病の治療方法
CA2124217A1 (fr) Inactivation de produits cytotoxiques
JP2837866B2 (ja) 口蹄疫に対する合成ワクチンおよびその製造方法
JPH0585942A (ja) インターフエロン−ヒアルロン酸及び／又はその塩の結合体
CA2155953A1 (fr) Conjugues de proteines; compositions qui en renferment et leur utilisation comme medicaments
WO2004011486A2 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990610

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030418